Oseltamivir Phosphate
A to Z Drug Facts
Oseltamivir Phosphate |
(oh-sell-TAM-ih-veer) |
Tamiflu |
Class: Anti-infective/Antiviral |
Action Inhibition of influenza virus neuraminidase with possible alteration of virus particle aggregation and release.
Indications Treatment of uncomplicated acute illness caused by influenza infection in patients > 1 yr who have been symptomatic for £ 2 days; prophylaxis of influenza in patients ³ 13 yr.
Contraindications Standard considerations.
Treatment of Influenza
ADULTS AND ADOLESCENTS ³ 13 YR: PO 75 mg twice daily for 5 days. Renal impairment (Ccr 10 to 30 mL/min): PO 75 mg once daily for 5 days. ADULTS AND CHILDREN ³ 1 YR (who cannont swallow capsules): Suspension PO £ 15 kg (£ 33 lbs) administer 30 mg (2.5 mL) twice daily. > 15 to 23 kg (> 33 to 51 lbs) administer 45 mg (3.8 mL) twice daily. > 23 to 40 kg (51 to 88 lbs) administer 60 mg (5 mL) twice daily > 40 kg (> 88 lbs) administer 75 mg (6.2 mL) twice daily.
Influenza Prophylaxis
ADULTS AND ADOLESCENTS ³ 13 YR: PO 75 mg once daily for ³ 7 days. Renal impairment (Ccr 10 to 30 mL/min): PO 75 mg every other day.
Interactions None well documented.
Lab Test Interferences None well documented.
RESP: Bronchitis. CNS: Insomnia; vertigo. GI: Nausea; vomiting.
Pregnancy: Category C. Lactation: Undetermined. Children: Influenza treatment: Safety and efficacy not established in children < 1 yr. Influenza prophylaxis: Safety and efficacy not established in children < 13 yr. Repeated courses: Safety and efficacy not established. Renal impairment: Administer with caution.
PATIENT CARE CONSIDERATIONS |
|
|
Books@Ovid
Copyright © 2003 Facts and Comparisons
David S. Tatro
A to Z Drug Facts